Alectinib, ceritinib, crizotinib i brigatinib per al tractament del càncer de pulmó no microcític localment avançat o metastàsic, posiyiu per la cinasa del limfoma anaplàstic (ALK)
Abstract
Lung cancer is the leading cause of cancer-related mortality around the world. The 2018 global estimates of the incidence of cancer and mortality for GLOBOCAN indicate a total of 2 million new cases and 1.7 million deaths related to lung cancer, which represents 11.5% of all cancer cases (except non-melanoma skin cancer) and 18.4% of all cancer deaths. In Spain, the expected incidence in 2018 was 27,351 new cases of lung cancer.
Keywords
Non-microcitic lung cancer; Kinase of anaplastic lymphoma; Adult patients
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Alectinib, ceritinib, crizotinib i brigatinib per al tractament del càncer de pulmó no microcític localment avançat o metastàsic, posiyiu per la cinasa del limfoma anaplàstic (ALK). Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4269This item appears in following collections
The following license files are associated with this item: